Taking peopleNo phase

A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis

Key facts

Who runs it: Imperial College London
Where: United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code: NCT06931002
Status: Recruiting
People taking part: 54 people, planned
Started: 24 Jul 2024
Expected to end: 30 Oct 2027
Type of study: Interventional
Treatments tested: Rhinovirus A-16 Infection
Record updated: 9 July 2025

Who can take part

Age: 18 years to 65 years
Sex: Women and men
Healthy volunteers: Can take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

For healthy volunteers:; Age 18 to 65 years
For bronchiectasis study subjects:; Confirmed diagnosis of bronchiectasis aged 18-65 years with bronchiectasis severity index score of 0-8 ; For Pseudomonas colonised individuals, isolation of Pseudomonas aeruginosa in two or more cultures, at least 3 months apart in a 2-year period

Who cannot take part

For bronchiectasis study subjects:; Individuals with bronchiectasis secondary to cystic fibrosis, primary immunodeficiency, primary ciliary dyskinesia and allergic bronchopulmonary aspergillosis 2) Individuals with other significant chronic lung disease diagnoses (eg. interstitial lung disease) which would impact the study in the opinion of the medical team 4) FEV1 < 50% predicted 8) Recent antibiotics for exacerbations within the preceding 6 weeks and prophylactic antibiotics (azithromycin or nebulised antibiotics) within preceding 4 weeks 9) Corticosteroid use (inhaled, nasal or systemic) within preceding 4 weeks
For healthy volunteers and bronchiectasis study subjects:; Any medical co-morbidity impacting the study in the opinion of the medical team; Current smoking history within last 12 months or ex smoking history >5 pack years; Pre-existing serum neutralising antibodies to RV-A16 (strain to be used for challenge); Close contact with infants or elderly individuals either at home or workplace; Pregnancy or breastfeeding

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 18 and 65 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this study is to determine if viral infection with the common cold leads to an exacerbation in participants with bronchiectasis. The investigators will compare the participants with bronchiectasis to a group of healthy participants. The main questions it aims to answer are:

Read full original descriptionShow less

* Does viral infection with the common cold lead to an exacerbation in bronchiectasis? * Does the immune response differ to that of a healthy participant?

Participants will attend for a screening visit to see if they are eligible. All participants who are eligible and have consented to take part will have baseline investigations done including blood tests and a bronchoscopy. They will be given a spray of a virus that causes the common cold into their nose. They will then be followed up over the next 6 weeks with some of the following procedures at each study visit; spirometry, nasosorption, nasal lavage, nasal brushing, blood test, sputum collection and a bronchoscopy. Participants will be asked to keep a daily record of their symptoms throughout the study.